AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 261 min read$SBEV

Endovia Health Sciences, Inc. (SBEV): Entry into a Material Definitive Agreement

Endovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich

Original reporting
SEC EDGAR 8-K
Published Aug 26, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$SBEV
Neutral
medium confidence
Mentioned
$SBEV
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBEVNeutralLow
01

Why it matters

The filing satisfies disclosure requirements; no immediate catalyst for price movement beyond standard leadership change.

02

Market read

Limited relevance; primarily a compliance filing with modest compensation details.

03

What to watch

Potential future capital raises tied to executive incentives if market cap targets are met.

Relevance 6/10Novelty 3/10Timing: filed Aug 26 2026

Background

Endovia Health Sciences filed a Form 8‑K announcing interim CEO and COO appointments with compensation details.

Company-level read

Ticker impact

$SBEVNeutralMedium confidence
Context

SEC 8‑K reports new interim CEO and COO employment agreements with salary, bonus and option terms.

Expected impact

Likely negligible movement; market may price in leadership change gradually.

Evidence & confidence

Employment contracts are disclosed for compliance; no large financial commitment or strategic shift disclosed.

Market effects

Sector

None significant; leadership change in a micro‑cap health‑science firm.

Regional

None

Global

None

Counterpoint

What could challenge this read

Leadership appointments could signal upcoming strategic initiatives that the market may undervalue.

Key entities

  • company
    Endovia Health Sciences, Inc.

    Micro‑cap health‑science company filing the 8‑K.

  • executive
    Brady Cobb

    Interim Chief Executive Officer.

  • executive
    Michael Bondurant

    Interim Chief Operating Officer.

Read at source← All news

Related articles

AUG 20
$SBEVLow

SPLASH BEVERAGE GROUP, INC. (SBEV): Results of Operations and Financial Condition

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L

SEC EDGAR 8-K1 min
JUL 31
$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

benzinga.com5 min
JUL 29
$SBEVMed

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

finanznachrichten.de4 min
JUL 14
$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

manilatimes.net4 min
JUL 9
$SBEVMed

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said NYSE American accepted its plan to regain continued listing compliance and granted a compliance period through Jan. 29, 2027, after the company submitted the plan on May 29, 2026. The company said it will execute strategic initiatives while maintaining its listing.

manilatimes.net3 min
JUL 7
$SBEVMedAI 8/10

SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (NYSE American: SBEV) said it signed an exclusive global licensing deal with Argent BioPharma (ASX/LSE: RGT) for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil is approved for distribution in multiple countries and has initiated U.S. pre-IND/IND steps. Splash received a $1M investment commitment and will issue $5.5M preferred equity; Argent debt (~$5M) is forgiven. Argent earns a 15% net-revenue royalty.

prnewswire.com3 min